Noxopharm Appoints new CEO
- Noxopharm Limited (NOX) announces a shift in leadership in preparation for an upcoming ‘growth phase’
- Dr Gisela Mautner has been appointed as CEO starting next month, with former CEO Dr Graham Kelly remaining on the board
- Dr Mautner joined Noxopham three years ago and oversaw the implementation of the company’s clinical programs
- Dr Kelly will remain actively involved in Noxophar m’s future given his previous impact on the company
- The company’s share price was up 4.9 percent to trade at 43 cents at midday AEDT
